HOME >> MEDICINE >> NEWS
New discovery may revolutionize treatment for pain related to surgery, illness and injury

For those suffering from pain, scientists from UCLA and the University of Cambridge, United Kingdom, report a revolutionary advance in pain medicine that promises to deliver painkillers directly to the affected area of the body, in smaller doses and with fewer side effects.

The researchers report the first clinically suitable method using nerves as a means of safely delivering high doses of painkillers to achieve a therapeutic effect. They announced their research findings at the Society for Neuroscience conference on Nov. 8 in New Orleans, La.

UCLA neurosurgeon Aaron Filler and his colleagues used a method called "axonal transport" to deliver a pain drug to the spinal ganglia and spinal cord, using nerves as a conduit, in an animal model.

Axonal transport works like a "conveyor-belt" process, delivering pain-relieving medication to remote sensory endings in the tissues of the body. In axonal transport, the cell moves molecules from one end of the cell to the other, thus supporting their ability to communicate with other neurons. A single neuron may be more than two feet long.

Although axonal transport has played a role in thousands of research studies in the past, this is the first-ever report of a positive clinical effect with a potential human medication. The new technology uses a novel molecular structure to achieve clinically effective dosing in targeted groups of nerves, Filler said.

This work marks an important advance, because drug treatment of nervous-system disorders is often hindered and sometimes precluded when the precise site of the injury or disease cannot be reached with adequate levels of pain medicine without causing unwanted side effects. Delivery of painkillers directly to selected target sites can avoid undesired toxicity, as well as inappropriate side effects in non-target neural tissue.

Filler says that with this new method of delivering pain medication, one shot administered during surgery coul
'"/>

Contact: Roxanne Yamaguchi Moster
roxannem@support.ucla.edu
310-794-2264
University of California - Los Angeles
7-Nov-2000


Page: 1 2 3

Related medicine news :

1. TB Alliance announces new drug discovery program with GlaxoSmithKline
2. Mayo Clinic discovery on nature of rheumatoid arthritis lung disease may offer patients therapy
3. Canadian researchers important discovery in HIV research
4. Long-sought key to hearing may be found in protein discovery
5. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
6. Lupus discovery may pave way to better-designed COX-2 inhibitors
7. New discovery may lead to therapy for incurable blood cancer
8. DuPont-led scientists unveil key nanotechnology discovery with use of DNA
9. Canadian discovery promises treatment for HIV dementia
10. Ann Arbor chemist wins national award for drug discovery
11. Zebrafish: Drug discovery of a different stripe holds promise in COX research

Post Your Comments:
(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... undergoing in vitro fertilization (IVF) are only about half as ... assisted reproduction technique, new research indicates, and the racial disparity ... study, about 31 percent of white patients became pregnant after ... Analyzing more than 4,000 IVF cycles over two years to ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... , 20 de octubre de 2014  PneumRx, ... campo de la pulmonología intervencional, anunció hoy la ... casi 3 meses antes de lo programado. El Estudio ... de dispositivo de investigación (IDE) aprobada por la ... sistema de espiral de reducción de volumen pulmonar ...
(Date:10/20/2014)... 20, 2014  ResMed (NYSE: RMD ... Data Exchange program, a comprehensive suite of software ... and other health care providers. ... critical patient information. It integrates valuable sleep and ... patient management platforms with customers, in-house or third-party ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
Cached News: